Many inflammatory signaling pathways are activated in several types of cancer, linking chronic inflammation to tumorigenesis process. Inflammation has a dual role in antitumor or peritumoral activity depending on the plasticity of immune cells, their phenotype in the inflammatory tumor microenvironment, and their secreting factors such as cytokines, chemokines, growth factors and proteolytic enzymes. However, the role of inflammatory mediators in cancer immunotherapy is still not clear. Inflammatory mediators such as cytokines, chemokines, growth factors, proteolytic enzymes produced by immune cells such as macrophages, neutrophils, and lymphocytes activate transcriptional factors and further downstream signaling pathway within the context of the tumor microenvironment, these critical factors may promote or inhibit the response of cancer immunotherapy. Identification of inflammatory mediators and their interactions with other tumors and stromal cells within the tumor microenvironment involved in cancer immunotherapy is important for future therapeutic strategy development of cancer immunotherapy.
Therefore, to identify critical inflammatory mediators and reveal their roles in cancer immunotherapy, this Research topic aims to focus on research progress in the novel biochemical mechanisms of inflammatory mediators in cancer immunotherapy. We welcome the submission of original research and review articles that include basic and clinical studies, as well as technological applications of inflammatory mediators in cancer immunotherapy.
Potential topics include but are not limited to the following:
1. Identification of novel cancer inflammatory mediators that involving in cancer immunotherapy.
2. Novel biomarkers of cancer inflammatory mediators for therapeutic response in cancer patients, which include but not limited to cancer immunotherapy.
3. Novel mechanisms of immune cells involved in the activation, migration, and infiltration of tumor immune microenvironment.
4. Multi-omics reveal the mechanisms of cross-talk between cancer cells and local immune cells.
5. Single-cell sequencing for revealing the heterogeneity of immune cells and the mechanism for inflammatory remodeling in tumor immune microenvironment.
6. The mechanism of mediators for anti-cancer or cancer-promoting tumor-associated macrophages in cancer immunotherapy.
7. Serum or tumor microenvironment biomarkers, such as circulating cell-free DNA (cfDNA), circulating tumor DNA (ctDNA), mRNA, microRNA (miRNA), circular RNA (circRNA), exosomal RNA (exRNA) and long non-coding RNA (IncRNA), for regulating inflammatory in cancer immunotherapy.
8. Intratumor microbiota affects the inflammatory progression in cancer immunotherapy.
9. Anti-Inflammatory or pro-inflammatory drugs and their mechanisms related to response or sensitivity to cancer immunotherapy.
10. Immune neoantigens involved in inflammatory response during tumor immunotherapy.
Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this topic.
Many inflammatory signaling pathways are activated in several types of cancer, linking chronic inflammation to tumorigenesis process. Inflammation has a dual role in antitumor or peritumoral activity depending on the plasticity of immune cells, their phenotype in the inflammatory tumor microenvironment, and their secreting factors such as cytokines, chemokines, growth factors and proteolytic enzymes. However, the role of inflammatory mediators in cancer immunotherapy is still not clear. Inflammatory mediators such as cytokines, chemokines, growth factors, proteolytic enzymes produced by immune cells such as macrophages, neutrophils, and lymphocytes activate transcriptional factors and further downstream signaling pathway within the context of the tumor microenvironment, these critical factors may promote or inhibit the response of cancer immunotherapy. Identification of inflammatory mediators and their interactions with other tumors and stromal cells within the tumor microenvironment involved in cancer immunotherapy is important for future therapeutic strategy development of cancer immunotherapy.
Therefore, to identify critical inflammatory mediators and reveal their roles in cancer immunotherapy, this Research topic aims to focus on research progress in the novel biochemical mechanisms of inflammatory mediators in cancer immunotherapy. We welcome the submission of original research and review articles that include basic and clinical studies, as well as technological applications of inflammatory mediators in cancer immunotherapy.
Potential topics include but are not limited to the following:
1. Identification of novel cancer inflammatory mediators that involving in cancer immunotherapy.
2. Novel biomarkers of cancer inflammatory mediators for therapeutic response in cancer patients, which include but not limited to cancer immunotherapy.
3. Novel mechanisms of immune cells involved in the activation, migration, and infiltration of tumor immune microenvironment.
4. Multi-omics reveal the mechanisms of cross-talk between cancer cells and local immune cells.
5. Single-cell sequencing for revealing the heterogeneity of immune cells and the mechanism for inflammatory remodeling in tumor immune microenvironment.
6. The mechanism of mediators for anti-cancer or cancer-promoting tumor-associated macrophages in cancer immunotherapy.
7. Serum or tumor microenvironment biomarkers, such as circulating cell-free DNA (cfDNA), circulating tumor DNA (ctDNA), mRNA, microRNA (miRNA), circular RNA (circRNA), exosomal RNA (exRNA) and long non-coding RNA (IncRNA), for regulating inflammatory in cancer immunotherapy.
8. Intratumor microbiota affects the inflammatory progression in cancer immunotherapy.
9. Anti-Inflammatory or pro-inflammatory drugs and their mechanisms related to response or sensitivity to cancer immunotherapy.
10. Immune neoantigens involved in inflammatory response during tumor immunotherapy.
Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this topic.
